Literature DB >> 29955527

Review of cariprazine in management of psychiatric illness.

Rebecca H Campbell1, Michael Diduch1, Kristen N Gardner2, Christopher Thomas3.   

Abstract

Schizophrenia and bipolar disorder are severe and debilitating psychiatric disorders. Despite the availability of numerous antipsychotic drugs, many patients still experience poor outcomes and treatment-limiting adverse side effects. Cariprazine is a novel antipsychotic with unique pharmacodynamic and pharmacokinetic properties. It is both a dopamine type 2 and dopamine type 3 partial agonist with 2 equipotent metabolites, desmethyl cariprazine and didesmethyl cariprazine, of which didesmethyl cariprazine has a half-life of 1 to 3 weeks. The objective of this article is to review the literature regarding efficacy and tolerability of cariprazine in the management of psychiatric disorders to determine its current place in therapy.

Entities:  

Keywords:  bipolar disorder; partial dopamine agonist; pharmacotherapy; schizophrenia

Year:  2018        PMID： 29955527      PMCID： PMC6007710          DOI： 10.9740/mhc.2017.09.221

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN： 2168-9709


  15 in total

1.  Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.

Authors:  Joseph R Calabrese; Paul E Keck; Anju Starace; Kaifeng Lu; Adam Ruth; István Laszlovszky; György Németh; Suresh Durgam
Journal:  J Clin Psychiatry       Date:  2015-03       Impact factor: 4.384

2.  An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.

Authors:  Suresh Durgam; Anju Starace; Dayong Li; Raffaele Migliore; Adam Ruth; György Németh; István Laszlovszky
Journal:  Schizophr Res       Date:  2014-01-10       Impact factor: 4.939

3.  Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.

Authors:  Suresh Durgam; Andrew J Cutler; Kaifeng Lu; Raffaele Migliore; Adam Ruth; István Laszlovszky; György Németh; Herbert Y Meltzer
Journal:  J Clin Psychiatry       Date:  2015-12       Impact factor: 4.384

4.  Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial.

Authors:  John M Kane; Stephen Zukin; Yao Wang; Kaifeng Lu; Adam Ruth; Krisztián Nagy; István Laszlovszky; Suresh Durgam
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

Review 5.  Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.

Authors:  Kim S J Lao; Ying He; Ian C K Wong; Frank M C Besag; Esther W Chan
Journal:  CNS Drugs       Date:  2016-11       Impact factor: 5.749

6.  Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.

Authors:  Gary S Sachs; William M Greenberg; Anju Starace; Kaifeng Lu; Adam Ruth; István Laszlovszky; György Németh; Suresh Durgam
Journal:  J Affect Disord       Date:  2014-11-24       Impact factor: 4.839

7.  The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.

Authors:  Suresh Durgam; Anju Starace; Dayong Li; Raffaele Migliore; Adam Ruth; György Németh; István Laszlovszky
Journal:  Bipolar Disord       Date:  2014-07-24       Impact factor: 6.744

8.  Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial.

Authors:  Suresh Durgam; Willie Earley; Rui Li; Dayong Li; Kaifeng Lu; István Laszlovszky; W Wolfgang Fleischhacker; Henry A Nasrallah
Journal:  Schizophr Res       Date:  2016-07-15       Impact factor: 4.939

9.  An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.

Authors:  Suresh Durgam; Willie Earley; Alan Lipschitz; Hua Guo; István Laszlovszky; György Németh; Eduard Vieta; Joseph R Calabrese; Lakshmi N Yatham
Journal:  Am J Psychiatry       Date:  2015-11-06       Impact factor: 18.112

10.  First-generation antipsychotics: not gone but forgotten.

Authors:  Claire R M Dibben; Golam M Khandaker; Benjamin R Underwood; Christopher O'Loughlin; Catherine Keep; Louisa Mann; Peter B Jones
Journal:  BJPsych Bull       Date:  2016-04
View more
  9 in total

1.  D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

Authors:  Yudao Shen; John D McCorvy; Michael L Martini; Ramona M Rodriguiz; Vladimir M Pogorelov; Karen M Ward; William C Wetsel; Jing Liu; Bryan L Roth; Jian Jin
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

2.  A study of the structure-affinity relationship in SYA16263; is a D2 receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?

Authors:  Edem K Onyameh; Barbara A Bricker; Suresh V K Eyunni; Chandrashekhar Voshavar; Uma M Gonela; Edward Ofori; Andrea Jenkins; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2020-12-14       Impact factor: 3.641

3.  Maternal cariprazine exposure inhibits embryonic and postnatal brain cholesterol biosynthesis.

Authors:  Thiago C Genaro-Mattos; Allison Anderson; Luke B Allen; Keri A Tallman; Ned A Porter; Zeljka Korade; Károly Mirnics
Journal:  Mol Psychiatry       Date:  2020-06-05       Impact factor: 15.992

4.  A case series of serious and unexpected adverse drug reactions under treatment with cariprazine.

Authors:  Johannes Heck; Johanna Seifert; Dirk O Stichtenoth; Christoph Schroeder; Adrian Groh; Gregor R Szycik; Detlef Degner; Ivana Adamovic; Michael Schneider; Catherine Glocker; Eckart Rüther; Stefan Bleich; Renate Grohmann; Sermin Toto
Journal:  Clin Case Rep       Date:  2021-05-04

5.  Cariprazine Use in Early Psychosis: Three Case Reports.

Authors:  Ricardo Coentre; Rodrigo Saraiva; Carolina Sereijo; Pedro Levy
Journal:  Front Psychiatry       Date:  2021-12-16       Impact factor: 4.157

6.  Cariprazine in Three Special Different Areas: A Real-World Experience.

Authors:  Camilla Gesi; Silvia Paletta; Maria Carlotta Palazzo; Bernardo Dell'Osso; Claudio Mencacci; Giancarlo Cerveri
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-07       Impact factor: 2.570

7.  Cardiometabolic outcomes among schizophrenia patients using antipsychotics: the impact of high weight gain risk vs low weight gain risk treatment.

Authors:  Rezaul Khandker; Farid Chekani; Brendan Limone; Ellen Thiel
Journal:  BMC Psychiatry       Date:  2022-02-19       Impact factor: 3.630

8.  Synthesis and biological evaluation of a new class of multi-target heterocycle piperazine derivatives as potential antipsychotics.

Authors:  Lanchang Gao; Chao Hao; Ru Ma; Jiali Chen; Guisen Zhang; Yin Chen
Journal:  RSC Adv       Date:  2021-05-07       Impact factor: 4.036

Review 9.  Multi-Target Approach for Drug Discovery against Schizophrenia.

Authors:  Magda Kondej; Piotr Stępnicki; Agnieszka A Kaczor
Journal:  Int J Mol Sci       Date:  2018-10-10       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.